Your browser doesn't support javascript.
loading
Recommendations for Post-Operative RadioTherapy After Complete Resection of Thymoma-a French DELPHI Consensus Initiative.
Basse, Clémence; Khalifa, Jonathan; Thillays, François; Le Pechoux, Cécile; Maury, Jean-Michel; Bonte, Pierre-Emmanuel; Coutte, Alexandre; Pourel, Nicolas; Bourbonne, Vincent; Pradier, Olivier; Belliere, Aurélie; Le Tinier, Florence; Deberne, Mélanie; Tanguy, Ronan; Denis, Fabrice; Padovani, Laetitia; Zaccariotto, Audrey; Molina, Thierry; Chalabreysse, Lara; Brioude, Geoffrey; Delatour, Bertrand; Faivre, Jean-Christophe; Cao, Kim; Giraud, Philippe; Riet, François-Georges; Thureau, Sébastien; Antoni, Delphine; Massabeau, Carole; Keller, Audrey; Bonnet, Emilie; Lerouge, Delphine; Martin, Etienne; Girard, Nicolas; Botticella, Angela.
Afiliação
  • Basse C; Institut du Thorax Curie-Montsouris, Institut Curie, Paris, France; Paris Saclay Campus, Versailles Saint Quentin University, Versailles, France.
  • Khalifa J; Department of Radiotherapy, Institut Claudius Rigaud, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
  • Thillays F; Department of Radiation Oncology, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Nantes, France.
  • Le Pechoux C; Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.
  • Maury JM; Department of Thoracic Surgery, Lung and Heart-Lung Transplantation, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France; IVPC UMR754 INRA, Univ Lyon, Université Claude Bernard Lyon 1, EPHE, Lyon, France.
  • Bonte PE; Biostatistics Department, Research Center, Institut Curie, Paris, France.
  • Coutte A; Department of Radiotherapy, Amiens Hospital, Amiens, France.
  • Pourel N; Radiation Department, Institut Sainte Catherine, Avignon, France.
  • Bourbonne V; Department of Radiotherapy, University Hospital of Brest, Brest, France.
  • Pradier O; Department of Radiotherapy, University Hospital of Brest, Brest, France.
  • Belliere A; Department of Radiotherapy, Centre Jean Perrin, Clermont-Ferrand, France.
  • Le Tinier F; Department of Radiotherapy, Centre Oscar Lambret, Lille, France.
  • Deberne M; Department of Radiotherapy, Hospices Civils Lyonnais, Lyon, France.
  • Tanguy R; Department of Radiotherapy, Hospices Civils Lyonnais, Lyon, France.
  • Denis F; Department of Radiotherapy, Centre de Cancérologie de la Sarthe, ELSAN, Le Mans, France.
  • Padovani L; Department of Radiotherapy, Assistance Publique Hôpitaux de Marseille, Marseille, France.
  • Zaccariotto A; Department of Radiotherapy, Assistance Publique Hôpitaux de Marseille, Marseille, France.
  • Molina T; Pathology Department, Necker Enfants Malades Hospital, Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
  • Chalabreysse L; Department of Pathology, Groupement Hospitalier Est, Bron Cedex Lyon, France.
  • Brioude G; Department of Thoracic Surgery, Disease of the Oesophagus and Lung Transplantations, Hôpital Nord, Aix-Marseille University, Marseille, France.
  • Delatour B; Department of Thoracic and Cardiovascular Surgery, Rennes University Hospital Center, Rennes, France.
  • Faivre JC; Department of Radiotherapy, Institut de Cancérologie de Lorraine, Nancy, France.
  • Cao K; Institut du Thorax Curie-Montsouris, Institut Curie, Paris, France.
  • Giraud P; Paris City University, Department of Radiation Oncology, Hopital Européen Georges Pompidou, Paris, France.
  • Riet FG; Department of Radiotherapy, Centre Hospitalier Privé Saint Grégoire, Rennes, France.
  • Thureau S; Department of Radiotherapy, Centre Henri Becquerel, Rouen, France.
  • Antoni D; Department of Radiotherapy, ICANS, Institut de Cancérologie de Strasbourg, Strasbourg, France.
  • Massabeau C; Department of Radiotherapy, Institut Claudius Rigaud, Toulouse, France.
  • Keller A; Department of Radiotherapy, Institut Claudius Rigaud, Toulouse, France.
  • Bonnet E; Department of Radiotherapy, IMR de Valence, Valence, France.
  • Lerouge D; Department of Radiation Oncology, Centre Baclesse, Caen, France.
  • Martin E; Department of Radiotherapy, Centre Georges-François-Leclerc, Dijon, France.
  • Girard N; Institut du Thorax Curie-Montsouris, Institut Curie, Paris, France; Paris Saclay Campus, Versailles Saint Quentin University, Versailles, France. Electronic address: nicolas.girard2@curie.fr.
  • Botticella A; Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.
J Thorac Oncol ; 19(7): 1095-1107, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38608932
ABSTRACT

INTRODUCTION:

Thymomas are rare intrathoracic malignancies that can relapse after surgery. Whether or not Post-Operative RadioTherapy (PORT) should be delivered after surgery remains a major issue. RADIORYTHMIC is an ongoing, multicenter, randomized phase 3 trial addressing this question in patients with completely R0 resected Masaoka-Koga stage IIb/III thymoma. Experts in the field met to develop recommendations for PORT.

METHODS:

A scientific committee from the RYTHMIC network identified key issues regarding the modalities of PORT in completely resected thymoma. A DELPHI method was used to question 24 national experts, with 115 questions regarding the following (1) imaging techniques, (2) clinical target volume (CTV) and margins, (3) dose constraints to organs at risk, (4) dose and fractionation, and (5) follow-up and records. Consensus was defined when opinions reached more than or equal to 80% agreement.

RESULTS:

We established the following

recommendations:

preoperative contrast-enhanced computed tomography (CT) scan is recommended (94% agreement); optimization of radiation delivery includes either a four-dimensional CT-based planning (82% agreement), a breath-holding inspiration breath-hold-based planning, or daily control CT imaging (81% agreement); imaging fusion based on cardiovascular structures of preoperative and planning CT scan is recommended (82% agreement); right coronary and left anterior descending coronary arteries should be delineated as cardiac substructures (88% agreement); rotational RCMI/volumetric modulated arc therapy is recommended (88% agreement); total dose is 50 Gy (81% agreement) with 1.8 to 2 Gy per fraction (94% agreement); cardiac evaluation and follow-up for patients with history of cardiovascular disease are recommended (88% agreement) with electrocardiogram and evaluation of left ventricular ejection fraction at 5 years and 10 years.

CONCLUSION:

This is the first consensus for PORT in thymoma. Implementation will help to harmonize practices.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Timoma / Neoplasias do Timo / Técnica Delphi / Consenso Limite: Humans País/Região como assunto: Europa Idioma: En Revista: J Thorac Oncol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Timoma / Neoplasias do Timo / Técnica Delphi / Consenso Limite: Humans País/Região como assunto: Europa Idioma: En Revista: J Thorac Oncol Ano de publicação: 2024 Tipo de documento: Article